ECOR 8-K
electroCore, Inc. (ECOR)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
(Address of principal executive offices and zip code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||
| The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On January 20, 2026, electroCore, Inc. (the “Company”) issued a press release providing a business update, including select unaudited preliminary financial guidance for the three and 12 months ended December 31, 2025. A copy of the press release is filed herewith as Exhibit 99.1.
Additionally, the executive officers of the Company have several upcoming presentations to representatives of investors and analysts. The presentation includes the select unaudited preliminary financial estimates for the three and 12 months ended December 31, 2025. The officers intend to use the material filed as Exhibit 99.2 herewith, in whole or in part, as part of those presentations.
The selected financial results in Exhibits 99.1 and 99.2 are based on preliminary unaudited information and management estimates, are not a comprehensive statement of the Company’s financial results for either the fourth quarter or fiscal year ended December 31, 2025 and are subject to change. Such changes may be material. Our independent registered public accounting firm has not conducted an audit or review of and does not express an opinion or provide any other form of assurance with respect to, these preliminary results.
The information furnished in this Item 2.02 of this Current Report on Form 8-K, Exhibit 99.1, and Exhibit 99.2, each attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 of this Current Report on Form 8-K, Exhibit 99.1, and Exhibit 99.2, shall not be incorporated by reference into any filing with the Securities and Exchange Commission (the “SEC”) made by the Company, whether made before or after the date hereof, except as shall be expressly set forth by reference in such filing.
The financial information set forth in this Current Report on Form 8-K, Exhibit 99.1, and Exhibit 99.2 reflects the Company’s current preliminary financial estimates, is subject to the completion of its audit process, and is subject to change. The Company’s fourth quarter and full year ended December 31, 2025 results could differ materially from the preliminary estimates provided in this Current Report on Form 8-K. Investors are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s estimates only as of the date of this Current Report on Form 8-K. Investors should refer to the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 12, 2025, as updated and supplemented by its other SEC reports filed from time to time, for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by these forward-looking statements. Given these risks, uncertainties and other factors, many of which are beyond the Company’s control, investors are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly release the results of any revision or update of the forward-looking statements, except as required by law.
Item 7.01. Regulation FD Disclosure.
The information set forth under Item 2.02, “Results of Operations and Financial Condition,” is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
Description of Exhibit | |
| 99.1 | Press release dated January 20, 2026. | |
| 99.2 | Investor Presentation dated January 20, 2026. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| electroCore, Inc. | |
| January 20, 2026 | /s/ Joshua S. Lev |
| Joshua S. Lev | |
| Chief Financial Officer |
Exhibit 99.1
electroCore Provides Preliminary Full-Year 2025 Business Update;
Expects ~26% Revenue Growth to ~$31.8–$32.0 Million
| ● | Record revenue of approximately $31.8 - $32.0 million for full-year 2025 and approximately $9.0 - $9.2 million for the three months ended December 31, 2025 | |
| ● | Revenue growth of approximately 26% over full-year 2024 | |
| ● | Cash, cash equivalents, and marketable securities (“Total Cash”) balance of approximately $11.6 million as of December 31, 2025 |
ROCKAWAY, N.J., January 20, 2026 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today provided select unaudited preliminary financial guidance for the full year and fourth quarter of 2025.
Financial Guidance
Preliminary unaudited financial guidance for the full year and fourth quarter of 2025:
Revenue: The Company anticipates reporting record full year 2025 revenue of approximately $31.8 - $32.0 million. This would represent approximately 26% growth over full-year 2024 revenue of $25.2 million. Fourth quarter 2025 revenue is anticipated to be approximately $9.0 - $9.2 million, which would represent approximately 30% growth over fourth quarter of 2024.
Cash Position: The Company ended 2025 with approximately $11.6 million of Total Cash compared to approximately $13.2 million as of September 30, 2025.
The Company intends to provide a detailed operational and financial update during its fourth quarter and full-year 2025 earnings call in March 2026.
About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about revenue expectations for the full-year and fourth quarter of 2025; cash position as of the year ended 2025, electroCore’s business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; business prospects around its prescription gammaCore and Quell Fibromyalgia devices, health and wellness products, Truvaga, and other new products and markets, and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” and other words of similar meaning, derivations of such words and the use of future dates. Preliminary business results and financial position are subject to change, possibly materially, as we complete our Annual Report on Form 10-K for the year ended Dec. 31, 2025. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, Quell Fibromyalgia, TAC-STIM, and Truvaga, electroCore’s results of operations and financial performance, macroeconomic factors including, but not limited to, inflation and currency fluctuations, competition in the industry in which electroCore operates and overall economic and market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
Contact:
ECOR Investor Relations
(973) 302-9253
Exhibit 99.2
